Success Metrics

Clinical Success Rate

87.5%

Based on 7 completed trials

Completion Rate

88%(7/8)

Active Trials

0(0%)

Results Posted

86%(6 trials)

Terminated

1(13%)

Phase Distribution

Ph phase_2

63%

Ph phase_3

25%

Ph phase_4

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 2Efficacy & side effects

5(62.5%)

Phase 3Large-scale testing

2(25.0%)

Phase 4Post-market surveillance

1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(7)

Terminated(1)

Detailed Status

Completed7

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

87.5%

Most Advanced

Phase 4

Trials by Phase

Phase 25 (62.5%)

Phase 32 (25.0%)

Phase 41 (12.5%)

Trials by Status

terminated113%

completed788%

Recent Activity

0 active trials

Showing 5 of 8

completedphase_2

A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients

NCT05244057

terminatedphase_3

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

NCT01821963

completedphase_3

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

NCT00627926

completedphase_2

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

NCT00420784

completedphase_2

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

NCT00535847

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT05244057Phase 2

A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients

Completed

NCT01821963Phase 3

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Terminated

NCT00627926Phase 3

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Completed

NCT00420784Phase 2

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Completed

NCT00535847Phase 2

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

Completed

NCT00336479Phase 2

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

Completed

NCT00372385Phase 2

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Completed

NCT00192569Phase 4

Australian Trial in Acute Hepatitis C

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8